SCHEMBL7055907

SCHEMBL7055907

CCc1ccc2nc(NC(=N)N)nc(C)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.61
RAB9A P51151 3/20 0.61
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
ALDH1A1 P00352 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
RAD52 P43351 2/20 0.56
HTT P42858 2/20 0.56
MAPT P10636 10/20 0.47
KDM4E B2RXH2 9/20 0.47
RECQL P46063 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 2/20 0.46
CYP1A2 P05177 1/20 0.46
ALPL P05186 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056202 0.90 LMNA (0.51) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7056204 0.89 LMNA (0.50) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7052853 0.87 LMNA (0.49) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7056709 0.86 LMNA (0.48) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL20077899 0.86 LMNA (0.47) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7058864 0.86 LMNA (0.47) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7056805 0.85 LMNA (0.47) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7054274 0.85 LMNA (0.47) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL7057908 0.85 LMNA (0.47) LMNARAB9AKMT2AMEN1ALDH1A1
SCHEMBL3470444 0.83 KDM4E (0.58) LMNARAB9AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176314-A1 Compounds for the treatment of pain H. LUNDBECK A/S (DK) 2003-09-18 US disclosed
US-20030139431-A1 Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors H. LUNDBECK A/S (DK) 2003-07-24 US disclosed
WO-2003026657-A1 COMPOUNDS FOR THE TREATMENT OF PAIN SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176314-A1 Compounds for the treatment of pain NPFFR2, NPFFR1, OPRL1 LMNA 4829/4885RAB9A 3568/4885KMT2A 2310/4885
US-20030139431-A1 Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors NPFFR1, NPFFR2, SSTR3 LMNA 2301/4885RAB9A 2019/4885KMT2A 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.